Go to content
UR Home

Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia

Müller-Tidow, C. ; Tschanter, P. ; Röllig, C. ; Thiede, C. ; Koschmieder, A. ; Stelljes, M. ; Koschmieder, S. ; Dugas, M. ; Gerss, J. ; Butterfaß-Bahloul, T. ; Wagner, R. ; Eveslage, M. ; Thiem, U. ; Krause, S. W. ; Kaiser, U. ; Kunzmann, V. ; Steffen, B. ; Noppeney, R. ; Herr, W. ; Baldus, C. D. ; Schmitz, N. ; Götze, K. ; Reichle, A. ; Kaufmann, M. ; Neubauer, A. ; Schäfer-Eckart, K. ; Hänel, M. ; Peceny, R. ; Frickhofen, N. ; Kiehl, M. ; Giagounidis, A. ; Görner, M. ; Repp, R. ; Link, H. ; Kiani, A. ; Naumann, R. ; Brümmendorf, T. H. ; Serve, H. ; Ehninger, G. ; Berdel, W. E. ; Krug, U.



Abstract

DNA methylation changes are a constant feature of acute myeloid leukemia. Hypomethylating drugs such as azacitidine are active in acute myeloid leukemia (AML) as monotherapy. Azacitidine monotherapy is not curative. The AML-AZA trial tested the hypothesis that DNA methyltransferase inhibitors such as azacitidine can improve chemotherapy outcome in AML. This randomized, controlled trial compared ...

plus


Owner only: item control page
  1. Homepage UR

University Library

Publication Server

Contact:

Publishing: oa@ur.de

Dissertations: dissertationen@ur.de

Research data: daten@ur.de

Contact persons